Cellular approaches to bioreductive drug mechanisms.
Mitomycin C is being used as an adjunct to ionizing radiation in the treatment of some solid tumors. A rationale for this is that radioresistant hypoxic cells in solid tumors will have enhanced sensitivity to this bioreductively activated drug, compared to aerobic cells. The role of oxygen concentration and enzymatic drug reduction in bioreductive drug activation have been investigated. Techniques are reviewed for the in vitro determination of the oxygen concentration dependency of bioreductive drug activation. One of these techniques, an open cell suspension system using Chinese hamster ovary cells, is described. Results are shown that indicate that the oxygen concentration dependency of toxicity of mitomycin C and one of its analogues profiromycin, though qualitatively complementing the oxygen dependency of ionizing radiation toxicity, are not quantitatively optimal. Using a mitomycin C resistant human cell strain (3437T) from a cancer prone family, a possible role for DT-diaphorase, an oxygen insensitive 2-electron transfer enzyme, is suggested. A correlation between a low level of DT-diaphorase in 3437T cells and mitomycin C resistance under aerobic exposure conditions is seen. Under hypoxic exposure conditions this resistance is lost, suggesting 1-electron transfer enzymes control hypoxic cell bioreductive activation. An activation role for DT-diaphorase in mitomycin C toxicity in the treatment of solid tumors is contrasted to a potential detoxification role for the enzyme with other xenobiotics in the cancer prone family phenotype.
Rauth
A M
AM
Division of Experimental Therapeutics, Ontario Cancer Institute, Toronto, Canada.
Marshall
R S
RS
Kuehl
B L
BL
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use* / Q000633:toxicity*; D016466:CHO Cells; D006224:Cricetinae; D006801:Humans; D016685:Mitomycin / Q000627:therapeutic use* / Q000633:toxicity*; D009369:Neoplasms / Q000188:drug therapy*; D010084:Oxidation-Reduction; D010100:Oxygen / Q000494:pharmacology; D011160:Porfiromycin / Q000633:toxicity
D000970:Antineoplastic Agents; D016685:Mitomycin; D011160:Porfiromycin; D010100:Oxygen